Advanced in Mycobacterium Avium Complex Infections

Shih-lung K. Cheng

TPQ, TW 
Advanced in Mycobacterium Avium Complex Infections
TPQ, TW 
OverviewLocationsClinical Research

Overview

Shih-lung Cheng practices in Taiwan. Cheng is rated as an Advanced expert by MediFind in the treatment of Mycobacterium Avium Complex Infections. Their top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Mycobacterium Avium Complex Infections, Nontuberculous Mycobacterial Lung Disease, and Bronchiectasis.

Their clinical research consists of co-authoring 77 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 5 articles in the study of Mycobacterium Avium Complex Infections.

Locations

TPQ, Taiwan
Other Locations
Taoyuan, TNQ, Taiwan
Taoyuan City, TNQ, Taiwan
Banqiao, TPQ, Taiwan
No. 122-23, Sec. 2, Nanya S Rd, 220 New Taipei City, Nanya, TPQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3

77 Total Publications

Prognostic risk profiling in COPD using Global Initiative for Chronic Obstructive Lung Disease 2023 ABE and comorbidity assessment: evidence from a register-based COPD cohort.
Prognostic risk profiling in COPD using Global Initiative for Chronic Obstructive Lung Disease 2023 ABE and comorbidity assessment: evidence from a register-based COPD cohort.
Journal: Journal of global health
Published: May 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Cheng's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile